Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd maintains a strong liquidity position, with a current ratio of 3.79, indicating the company can cover its short-term liabilities more than three times over. The company's liquidity_fpt score suggests it has sufficient operating cash flow to meet its obligations, though it is not in a position of high liquidity. The company's free cash flow of INR 54.58 million supports its operational flexibility and capacity for reinvestment. In terms of profitability, Shukra Pharmaceuticals Ltd demonstrates a return on equity (ROE) of 15.24% and a return on assets (ROA) of 11.04%, both of which are strong indicators of efficient capital use and asset management. These figures suggest the company is performing well relative to its equity and asset base, though a direct comparison to industry medians is not available in the current dataset. The company's operating margin, derived from its operating income of INR 97.25 million on revenue of INR 325.87 million, is also robust, indicating effective cost control and pricing power. The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic breakdown provided in the available data. This lack of diversification may expose the company to higher risk if demand in its primary market fluctuates. However, the absence of geographic segmentation also means the company is not overly reliant on any one region, which could be a mitigating factor. Looking ahead, the company's revenue is expected to grow in the current fiscal year, though the exact percentage is not disclosed in the available data. The company's capital expenditure of INR -27.43 million suggests it is not currently investing heavily in new infrastructure or expansion, which may indicate a focus on maintaining existing operations rather than aggressive growth. This could be a strategic decision to preserve cash or a sign of limited growth opportunities in the near term. The risk assessment for Shukra Pharmaceuticals Ltd indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 0.07 is low, suggesting it is not heavily leveraged and has a strong equity base. However, the note that net cash is negative after subtracting total debt implies the company may have some short-term liquidity constraints. The dilution risk is low, and no significant dilution events are expected in the near term, as the number of shares outstanding has not changed between basic and diluted figures. Recent events, including filings and transcripts, are not detailed in the available data, so no specific recent developments can be cited. The company's financials suggest a stable and profitable operation, but without additional disclosures, it is difficult to assess the impact of external factors such as regulatory changes or competitive pressures.